Robert E. Landry - Mar 16, 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Stock symbol
REGN
Transactions as of
Mar 16, 2022
Transactions value $
-$315,832
Form type
4
Date filed
3/18/2022, 04:08 PM
Previous filing
Dec 14, 2021
Next filing
Mar 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Sale -$203K -300 -1.03% $677.00 29K Mar 16, 2022 Direct F1
transaction REGN Common Stock Sale -$56.9K -83 -0.29% $686.00 28.9K Mar 17, 2022 Direct F1
transaction REGN Common Stock Options Exercise $139K +365 +1.26% $381.92 29.2K Mar 17, 2022 Direct
transaction REGN Common Stock Tax liability -$195K -286 -0.98% $682.50 29K Mar 17, 2022 Direct
holding REGN Common Stock 229 Mar 16, 2022 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -365 -1.87% $0.00 19.2K Mar 17, 2022 Common Stock 365 $381.92 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.